|
1
|
World Health Organization. Cancer. Fact
Sheet. 297:http://www.who.int/mediacentre/factsheets/fs297/en/.
Accessed February, 2012
|
|
2
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soda H, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lipson D, Capelletti M, Yelensky R, et al:
Identification of new ALK and RET gene fusions from colorectal and
lung cancer biopsies. Nat Med. 18:382–384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kohno T, Ishikawa H, Totoki Y, et al:
KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takeuchi K, Soda M, Togashi Y, et al: RET,
ROS and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell cancers.
Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Itoh K, Chiba T, Takahashi S, et al: An
Nrf2/small Maf heterodimer mediates the induction of phase II
detoxifying enzyme genes through antioxidant response elements.
Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rushmore TH and Kong AN: Pharmacogenomics,
regulation and signaling pathways of phase I and II detoxifying
enzymes. Curr Drug Metab. 3:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ngyyen T, Yang CS and Pickett CB: The
pathways and molecular mechanisms regulating Nrf2 activation in
response to chemical stress. Free Radic Biol Med. 37:433–441. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fahey JW and Kensler TW: Role of dietary
supplements/nutraceuticals in chemoprevention through induction of
cytoprotective enzymes. Chem Res Toxicol. 20:572–576. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kensler TW, Wakabayashi N and Biswal S:
Cell survival responses to environmental stresses via the
Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 47:89–116.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar
|
|
15
|
Arisawa T, Tahara T, Shibata T, et al:
Nrf2 gene promoter polymorphism and gastric carcinogenesis.
Hepatogastroenterology. 55:750–754. 2008.PubMed/NCBI
|
|
16
|
Shibata T, Ohta T, Tong KI, et al: Cancer
related mutations in NRF2 impair its recognition by Keap1-Cul3 E3
ligase and promote malignancy. Proc Natl Acad Sci USA.
105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sasaki H, Hikosaka Y, Okuda K, et al:
NFE2L2 gene mutation in male Japanese squamous cell carcinoma of
the lung. J Thorac Oncol. 5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wittwer CT, Herrmann MG, Moss AA and
Rasmussen RP: Continuous fluorescence monitoring of rapid cycle DNA
amplification. Biotechniques. 22:130–138. 1997.PubMed/NCBI
|
|
19
|
Pals G, Pindolia K and Worsham MJ: A rapid
sensitive approach to mutation detection using real-time polymerase
chain reaction and melting curve analyses, using BRCA1 as an
example. Mol Diagn. 4:241–246. 1999. View Article : Google Scholar
|
|
20
|
Sasaki H, Endo K, Konishi A, et al: EGFR
mutation status in Japanese lung cancer patients: genotyping
analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Itoh K, Wakabayashi N, Katoh Y, et al:
Keap1 represses nuclear activation of antioxidant responsive
elements by Nrf2 through binding to the amino-terminal Neh2 domain.
Genes Dev. 13:76–86. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yokota K, Sasaki H, Okuda K, et al:
KIF5B/RET fusion gene in surgically-treated Japanese adenocarcinoma
of the lung. Oncol Rep. 28:1187–1192. 2012.PubMed/NCBI
|
|
24
|
Hu Y, Ju Y, Lin D, et al: Mutation of the
Nrf2 gene in non-small cell lung cancer. Mol Biol Rep.
39:4743–4747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ahrendt SA, Decker PA, Alawi EA, et al:
Cigarette smoking is strongly associated with mutation of the Kras
gene in patients with primary adenocarcinoma of the lung. Cancer.
92:1525–1530. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stratton MR, Campbell PJ and Futreal PA:
The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar
|
|
27
|
Muller T and Hengstermann A: Nrf2: friend
and foe in preventing cigarette smoking-dependent lung disease.
Chem Res Toxicol. 25:1805–1824. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
29
|
Zhou J, Scmid T, Schnitzer S and Brune B:
Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006.
View Article : Google Scholar
|
|
30
|
Homma S, Ishii Y, Morishima Y, et al: Nrf2
enhances cell proliferation and resistance to anticancer drugs in
human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sasaki H, Shitara M, Yokota K, et al: MRP3
gene expression correlates with NRF2 mutations in lung squamous
cell carcinomas. Mol Med Rep. 6:705–708. 2012.PubMed/NCBI
|
|
32
|
Leinonen HM, Ruotsalainen AK, Määttä AM,
et al: Oxidative stress-regulated lentiviral TK/GCV gene therapy
for lung cancer treatment. Cancer Res. 72:6227–6235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
